View printer-friendly version

Brisbane, Australia, 5 July 2022 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that its patent, "Methods and apparatus for cough detection in background noise environments" has been granted in Australia (patent number 2018214442) and Japan (patent number JP,7092777,B).

The patent covers the use of machine learning audio processing techniques for detecting cough sounds in environments with significant background noise. The technology covered by the patent is used in ResApp's smartphone-based respiratory diagnostic test ResAppDx and its cough counting software ResAppCC.

The patent is owned by ResApp Health and has previously been granted in Europe. ResApp has additional patent applications covering similar subject matter pending in China, India and the United States.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

ResApp Health Limited published this content on 05 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 July 2022 00:03:04 UTC.